MUR AND NMS RESPIRATORY TOOLKIT. Sian Retallick (C) Devon LPC - - PowerPoint PPT Presentation

▶
mur and nms
SMART_READER_LITE
LIVE PREVIEW

MUR AND NMS RESPIRATORY TOOLKIT. Sian Retallick (C) Devon LPC - - PowerPoint PPT Presentation

Nov 25, 2023 312 likes •483 views

MUR AND NMS RESPIRATORY TOOLKIT. Sian Retallick (C) Devon LPC 20/01/2017 WHAT IS IMPORTANT TO KNOW? The Quality Payment Scheme is the new addition to the pharmacy contract It is a voluntary self assessment covering a number of areas:

slide-1
SLIDE 1

(C) Devon LPC

MUR AND NMS RESPIRATORY TOOLKIT.

Sian Retallick

20/01/2017

slide-2
SLIDE 2

(C) Devon LPC

WHAT IS IMPORTANT TO KNOW?

  • The Quality Payment Scheme is the new addition to the

pharmacy contract

  • It is a voluntary self assessment covering a number of

areas: Patient safety, Patient experience, Public Health, Digital, Clinical effectiveness, and Workforce

  • If pharmacy can achieve good results in the Quality

Scheme it will benefit the sector in moving toward a service lead future

  • Asthma is an area where community pharmacy can a

huge difference to good patient care

  • The Clinical effectiveness Quality Payment – ‘over use of

asthma (reliever)treatments’ is likely to be worth circa £1,700

20/01/2017

slide-3
SLIDE 3

(C) Devon LPC

WHY IS ASTHMA BEING TARGETED FOR MUR’S AND NMS ?

  • 5.4 million people in the UK are currently receiving

treatment for asthma: 1.1 million children (1 in 11) and 4.3 million adults (1 in 12).

  • Asthma prevalence is thought to have plateaued

since the late 1990s, although the UK still has some of the highest rates in Europe and on average 3 people a day die from asthma.

  • In 2014 (the most recent data available) 1216

people died from asthma.

  • The NHS spends around 1 billion a year treating and

caring for people with asthma.

  • Chronic obstructive pulmonary disease (COPD) is the

name for a collection of lung diseases, including chronic bronchitis, emphysema and chronic

  • bstructive airways disease.
  • It affects an estimated 3 million people in the UK.

20/01/2017

slide-4
SLIDE 4

(C) Devon LPC

BENEFITS OF MUR’S / NMS

  • improve medicines adherence
  • increase patient engagement with their condition

and medicines, which will support them in making decisions about their treatment and self management

  • reduce medicines wastage
  • reduce hospital admissions due to adverse events

associated with medicines

  • increase reporting of medicine adverse reactions

by pharmacists and patients

  • positive patient assessments
  • provide evidence base on the effectiveness of

the service

  • enable the development of outcome and/or

quality measures for community pharmacy

  • For MUR’s limited to 400 per year can generate

£11200.

  • NMS is unlimited range £20 - £28 per intervention.

20/01/2017

slide-5
SLIDE 5

(C) Devon LPC

WHY FOCUS ON ASTHMA AND COPD FOR MUR’S AND NMS ?

  • To access Quality payments the

contractor must be offering MUR’s or NMS or be registered for NHS Urgent Medicines Supply.

  • Over 90% of pharmacies provide Mur’s

and NMS.

  • Results of a Independent academic

evaluation (2014) gave a positive reinforcement for the service with improved patient outcomes and reduced cost for the NHS.

20/01/2017

slide-6
SLIDE 6

(C) Devon LPC

PART OF THE QUALITY PAYMENTS !

  • Asthma patients dispensed more than 6 short

acting bronchodilator inhalers without any corticosteroid inhaler within a 6-month period are referred to an appropriate health care professional for an asthma review.

  • There are two review points for this criterion:
  • · Friday 28th April 2017; and

· Friday 24th November 2017.

  • At each review point, meeting this criterion is

worth 10 points (£640), therefore a total of 20 points (£1,280) can be claimed in 2017 for achieving this criterion.

20/01/2017

slide-7
SLIDE 7

(C) Devon LPC

CHALLENGES FACING THE PHARMACY TEAM

  • How will we monitor "reliever "
  • veruse is Asthmatic patients.
  • How will our referral pathway to

GP's be made to ensure a clinical review is undertaken.

  • How will we keep to targets and

deadlines.

  • How will this information be

recorded in our Pharmacies.

20/01/2017

slide-8
SLIDE 8

PP

PHARMACY ASTHMA REFERRALS

slide-9
SLIDE 9

P

PSNC RESOURCES

slide-10
SLIDE 10

(C) Devon LPC

CPPE SUPPORT .

  • The Centre for Pharmacy Postgraduate

Education (CPPE) has a distance learning course and e-assessment on asthma, as well as inhaler technique training e- learning and videos, which pharmacists

  • r pharmacy technicians may find

useful to complete before incorporating the QP criterion into their daily practice.

20/01/2017

slide-11
SLIDE 11

(C) Devon LPC

ASTHMA BTS GUIDELINES.

  • While you would normally recommend the

NICE COPD guideline over the GOLD guideline, the NICE COPD guideline is out of date, having not been updated since 2010.

  • NICE undertakes a more comprehensive review of

the evidence and prepares their guidance in the context of the English/Welsh NHS.

  • NICE also involves GPs and nurses in developing their

guideline.

  • The next review of the NICE guideline was scheduled

to start in May 2016 , so we cannot expect a revised version until late 2017 or early 2018.

  • Clearly there have been many new treatment
  • ptions introduced since 2010, which are therefore

not covered by NICE currently.

20/01/2017

slide-12
SLIDE 12

(C) Devon LPC

ASTHMA RESOURCES

  • BTS ( New British Guidelines for the

management of asthma)

  • Devon Formulary ( Inhaler technique

videos and checklists)

  • Asthma UK (Asthma Action Plans)
  • In-Check Inspiratory Flow Measurement

Device

  • Inhaler technique training videos /

CPPE Online

  • Teva Respiratory Resources

20/01/2017

slide-13
SLIDE 13

(C) Devon LPC

COPD RESOURCES.

  • Devon Formulary (Formulary choices, Inhaler

technique videos and checklists, COPD self management plans and rescue packs

  • British Lung Foundation (COPD Passport)
  • Cat COPD Assessment Test
  • PCRS - (MRC Dyspnoea scale)
  • COPD /CPPE Online learning
  • COPD – new medicines /CPPE Online

learning

  • Teva Respiratory Resources

20/01/2017

slide-14
SLIDE 14

(C) Devon LPC

SAFEGUARDING .

  • Safeguarding training is a staff training

requirement for many locally commissioned services, such as emergency hormonal contraception.

  • The General Pharmaceutical Council

has also stated that pharmacy professionals and the pharmacy team working in community pharmacies are well placed to identify people who may be vulnerable.

  • Level 2 safeguarding training may be

available to pharmacy staff via local training sessions organised by Clinical Commissioning Groups, NHS England, local authorities or other providers, including in-house training.

  • Alternatively, the CPPE Safeguarding

children and vulnerable adults e- learning and e-assessment meets the level 2 requirements.

20/01/2017

slide-15
SLIDE 15

(C) Devon LPC

ONE LAST THING ?

  • One of the Quality Payment criteria

is:

  • ‘On the day of the review 80% of

registered pharmacy professionals working at the pharmacy have achieved level 2 safeguarding status for children and vulnerable adults in the last two years.’

20/01/2017

slide-16
SLIDE 16

(C) Devon LPC

GO FOR IT !

  • Any Questions !

20/01/2017